Overview

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Salmeterol Xinafoate